The Role of β Cell Glucagon-like Peptide-1 Signaling in Glucose Regulation and Response to Diabetes Drugs
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
SUMMARY Glucagon-like peptide-1 (GLP-1), an insulinotropic peptide released from the intestine after eating, is essential for normal glucose tolerance (GT). To determine whether this effect is mediated directly by GLP-1 receptors (GLP1R) on islet β-cells, we developed mice with β-cell specific knockdown of Glp1r. β-cell Glp1r knockdown mice had impaired GT after intraperitoneal (IP) glucose, and did not secrete insulin in response to IP or intravenous GLP-1. However, they had normal GT after oral glucose, a response that was impaired by a GLP1R antagonist. β-cell Glp1r knockdown mice had blunted responses to a GLP1R agonist, but intact glucose lowering with a DPP-4 inhibitor. Thus, in mice, β-cell Glp1r are required to respond to hyperglycemia and exogenous GLP-1, but other factors compensate for reduced GLP-1 action on the β-cell during meal ingestion. These results support a role for extra-islet GLP1R in oral glucose tolerance and paracrine regulation of β-cells by islet GLP-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“First, GLP-1 circulates in relatively low concentrations and postprandial changes in plasma levels are modest compared to other gut hormones (Baggio and Drucker, 2007; Vilsbøll et al., 2003).”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528 · cited 1×
“First, GLP-1 circulates in relatively low concentrations and postprandial changes in plasma levels are modest compared to other gut hormones (Baggio and Drucker, 2007; Vilsbøll et al., 2003).”
BackgroundVahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0153 · Cited by 318 · cited 2×
“Finally, there is growing evidence that GLP-1 regulates glucose metabolism indirectly via GLP1R expressed on peripheral and central neurons (Donath and Burcelin, 2013; Vahl et al., 2007; Waget et al., 2011).”
BackgroundResultSelf-citationExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
De Marinis, Y. Z., Salehi, A., Ward, C. E., Zhang, Q., Abdulkader, F., Bengtsson, M., Braha, O., Braun, M., Ramracheya, R., Amisten, S., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.007 · Cited by 257
Brain glucose sensing and neural regulation of insulin and glucagon secretion
Thorens, B. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01453.x · Cited by 198 · cited 1×
“causes hyperglycemia but does not affect the release of gastrointestinal hormones or the neural activation that contribute to insulin secretion after meals (Thorens, 2011), these results suggest that b cell GLP1Rs are needed for normal b cell sensitivity to hyperglycemia, independent of acute changes in circulating GL…”
ResultEffect of endogenous GLP-1 on insulin secretion in type 2 diabetes
Salehi, M., Aulinger, B., Prigeon, R. L., & D'Alessio, D. A. (2010) · Diabetes · doi:10.2337/db09-1253 · Cited by 124 · cited 1×
“This effect has also been demonstrated in humans whereby Ex-9 reduces glucose-stimulated insulin release during fasting when plasma GLP-1 is low and unchanging (Salehi et al., 2010; Schirra et al., 1998).”
BackgroundSelf-citationKaihara, K. A., Dickson, L. M., Jacobson, D. A., Tamarina, N., Roe, M. W., Philipson, L. H., & Wicksteed, B. (2013) · Diabetes · doi:10.2337/db12-1013 · Cited by 80 · cited 2×
“Transgenic Lines The MIPcreER line generation has been previously described (Kaihara et al., 2013; Wicksteed et al., 2010) with more characterization in the Supplemental Information (see also Figure S2 and Figure S2 legend).”
MethodSelf-citation
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“Conversely, mice with conditional selective genetic knockdown of Glp1r in b cells exhibited impairment of intraperitoneal glucose tolerance and defective insulin secretion following parenteral, but not oral, glucose administration (Smith et al., 2014).”
BackgroundMechanisms controlling pancreatic islet cell function in insulin secretion
Campbell, J. E., & Newgard, C. B. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00317-7 · Cited by 629
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Self-citationRecent advances in neuropeptide signaling in Drosophila, from genes to physiology and behavior
Nässel, D. R., & Zandawala, M. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.02.003 · Cited by 355
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Iwasaki, Y., Sendo, M., Dezaki, K., Hira, T., Sato, T., Nakata, M., Goswami, C., Aoki, R., Arai, T., Kumari, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02488-y · Cited by 200
The L-cell in nutritional sensing and the regulation of appetite
Spreckley, E. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2015.00023 · Cited by 198
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Osteoarthritis treatment via the GLP-1–mediated gut-joint axis targets intestinal FXR signaling
Yang, Y., Hao, C., Jiao, T., Yang, Z., Li, H., Zhang, Y., Zhang, W., Doherty, M., Sun, C., Yang, T., et al. (2025) · Science · doi:10.1126/science.adt0548 · Cited by 160
Burmeister, M. A., Ayala, J. E., Smouse, H., Landivar-Rocha, A., Brown, J. D., Drucker, D. J., Stoffers, D. A., Sandoval, D. A., Seeley, R. J., & Ayala, J. E. (2017) · Diabetes · doi:10.2337/db16-1102 · Cited by 136
Self-citationTargeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
El, K., Gray, S. M., Capozzi, M. E., Knuth, E. R., Jin, E., Svendsen, B., Clifford, A., Brown, J. L., Encisco, S. E., Chazotte, B. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf1948 · Cited by 132
Self-citationIs GLP‐1 a hormone: Whether and When?
D'Alessio, D. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12466 · Cited by 130
Self-citationRamracheya, R., Chapman, C., Chibalina, M., Dou, H., Miranda, C., González, A., Moritoh, Y., Shigeto, M., Zhang, Q., Braun, M., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13852 · Cited by 128
Ronveaux, C. C., Tomé, D., & Raybould, H. E. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.206029 · Cited by 124
The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
El, K., Douros, J. D., Willard, F. S., Novikoff, A., Sargsyan, A., Perez-Tilve, D., Wainscott, D. B., Yang, B., Chen, A., Wothe, D., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00811-0 · Cited by 118
“We first used islets isolated from mice with selective deletion of the Gipr in beta cells in combination with the GLP-1R antagonist exendin(9-39) (Ex9).”
BackgroundMethodInfluentialSelf-citationZhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., et al. (2019) · Diabetes · doi:10.2337/db18-0317 · Cited by 104
“The effects of GLP-1 on b-cells are mediated by the GLP-1 receptor (GLP1R), which activates various pathways to promote insulin secretion and b-cell survival (3,4).”
BackgroundResultVarin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104
“Glp1r / mice exhibit impaired glucose tolerance (Scrocchi et al., 1996), and selective deletion or restoration of the GLP1R within murine b cells of Glp1r / mice reveals an essential role for the b cell GLP-1R in glucose homeostasis (Lamont et al., 2012; Smith et al., 2014).”
BackgroundResultInfluentialSelf-citationMulvihill, E. E., Varin, E. M., Gladanac, B., Campbell, J. E., Ussher, J. R., Baggio, L. L., Yusta, B., Ayala, J., Burmeister, M. A., Matthews, D., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.007 · Cited by 102
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Pharmacological antagonism of the incretin system protects against diet-induced obesity
Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.018 · Cited by 67
Self-citationCorrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
Borner, T., Workinger, J. L., Tinsley, I. C., Fortin, S. M., Stein, L. M., Chepurny, O. G., Holz, G. G., Wierzba, A. J., Gryko, D., Nexø, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107768 · Cited by 39
Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists
Reed, J., Kanamarlapudi, V., & Bain, S. (2018) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000147 · Cited by 16
Updating the Role of α-Cell Preproglucagon products on GLP-1 receptor–mediated insulin secretion
Sandoval, D. (2020) · Diabetes · doi:10.2337/dbi19-0027 · Cited by 12
Metadata
- Authors
- Smith, E. P., An, Z., Wagner, C., Lewis, A. G., Cohen, E. B., Li, B., Mahbod, P., Sandoval, D., Perez-Tilve, D., Tamarina, N., Philipson, L. H., Stoffers, D. A., Seeley, R. J., & D’Alessio, D. A.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 19
- Issue
- 6
- Pages
- 1050-1057
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2035924200
- Cited by
- 164
- References
- 10
- FWCI
- 18.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.